[
  {
    "ts": null,
    "headline": "AbbVie Secures FDA Approval to Expand Mavyret’s Label",
    "summary": "AbbVie Inc. (NYSE:ABBV) is one of the best stocks for a dividend stock portfolio. The company announced that the US FDA has expanded the approved use of its oral antiviral drug Mavyret, developed in partnership with Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), for treating Hepatitis C. The updated approval allows Mavyret—made from the antiviral agents glecaprevir and […]",
    "url": "https://finnhub.io/api/news?id=4e25e269621c1ac88fa56edb7c95edb7a29ba2d37414b337846aad352b0166ff",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749845938,
      "headline": "AbbVie Secures FDA Approval to Expand Mavyret’s Label",
      "id": 135258979,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie Inc. (NYSE:ABBV) is one of the best stocks for a dividend stock portfolio. The company announced that the US FDA has expanded the approved use of its oral antiviral drug Mavyret, developed in partnership with Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), for treating Hepatitis C. The updated approval allows Mavyret—made from the antiviral agents glecaprevir and […]",
      "url": "https://finnhub.io/api/news?id=4e25e269621c1ac88fa56edb7c95edb7a29ba2d37414b337846aad352b0166ff"
    }
  },
  {
    "ts": null,
    "headline": "FDA approves label expansion of AbbVie hepatitis C therapy",
    "summary": "The decision is based on data from a Phase III, single-arm, prospective multicentre trial.",
    "url": "https://finnhub.io/api/news?id=1dff2e0c2271f8e5bde558a67fdb6110ccb15fa65c02bac93e4d5311b50c1e1a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749803314,
      "headline": "FDA approves label expansion of AbbVie hepatitis C therapy",
      "id": 135237308,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "The decision is based on data from a Phase III, single-arm, prospective multicentre trial.",
      "url": "https://finnhub.io/api/news?id=1dff2e0c2271f8e5bde558a67fdb6110ccb15fa65c02bac93e4d5311b50c1e1a"
    }
  }
]